Sweden's SyntheticMR Q4 sales rise 42% yr/yr

Syntheticmr publ AB

06/02/2026 07:44

Overview

Sweden-based imaging solutions firm's Q4 net sales rose 42% yr/yr

Company's Q4 operating loss narrowed

Regulatory approvals in Europe and India expanded market reach

Outlook

SyntheticMR aims to reach profitability through sharper commercial execution and cost discipline

Company focuses on U.S. market growth and efficiency improvements

Demand for MRI follow-ups driven by new Alzheimer’s treatments presents growth prospects

Result Drivers

APAC GROWTH - Strong performance in APAC driven by OEM sales in Japan, deepening partnerships

REGULATORY APPROVALS - cMRI-ARIA and cMRI received regulatory approvals in Europe and India, expanding market reach

U.S. MARKET CHALLENGES - U.S. market underperformed due to difficulty in securing research grants, shifting focus to clinical sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
SEK 18 mln
SEK 13 mln (1 Analyst)
Q4 Net Income
-SEK 6 mln
Q4 Operating Profit
-SEK 5.30 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for SyntheticMR AB (publ) is SEK2.23, about 99% above its February 5 closing price of SEK1.12

Press Release: ID:nWkr1NHKRZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)